Aarthi Jayanthan

发表

The dawn of targeted therapies for triple negative breast cancer (TNBC): a snapshot of investigational drugs in phase I and II trials

S. Dunn, A. Dorr, G. Los, 2020, Expert opinion on investigational drugs.

Occurrence and modulation of therapeutic targets of Aurora kinase inhibition in pediatric acute leukemia cells

A. Narendran, T. Cooper, S. Lotfi, 2013, Leukemia & lymphoma.

Targeting the Bcl-2 family of proteins in Hodgkin lymphoma: in vitro cytotoxicity, target modulation and drug combination studies of the Bcl-2 homology 3 mimetic ABT-737

J. Whitlock, T. Horton, S. Howard, 2009, Leukemia & lymphoma.

Aurora Kinases as Druggable Targets in Pediatric Leukemia: Heterogeneity in Target Modulation Activities and Cytotoxicity by Diverse Novel Therapeutic Agents

A. Narendran, T. Truong, Aarthi Jayanthan, 2014, PloS one.

Double‐deleted vaccinia virus in virotherapy for refractory and metastatic pediatric solid tumors

R. Johnston, J. Bell, P. Forsyth, 2013, Molecular oncology.

Human SNF5 arming of double-deleted vaccinia virus shows oncolytic and cytostatic activity against central nervous system atypical teratoid/rhabdoid tumor cells

Chunfen Zhang, A. Narendran, X. Lun, 2020, Cancer Gene Therapy.

Effects of 17-Allylamino-17-Demethoxygeldanamycin (17-AAG) on Pediatric Acute Lymphoblastic Leukemia (ALL) with Respect to Bcr-Abl Status and Imatinib Mesylate Sensitivity

A. Narendran, Aarthi Jayanthan, L. Hawkins, 2005, Pediatric Research.

CHILDHOOD ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) PRESENTING WITH SEVERE OSTEOLYSIS: A Model to Study Leukemia-Bone Interactions and Potential Targeted Therapeutics

A. Narendran, P. Miettunen, Clara L. Ortiz-Neira, 2010, Pediatric hematology and oncology.

Systematic in-vitro evaluation of the NCI/NIH Developmental Therapeutics Program Approved Oncology Drug Set for the identification of a candidate drug repertoire for MLL-rearranged leukemia

R. Arceci, A. Narendran, T. Trippett, 2011, OncoTargets and therapy.

Cytotoxicity, drug combinability, and biological correlates of ABT‐737 against acute lymphoblastic leukemia cells with MLL rearrangement

R. Stam, J. Whitlock, A. Narendran, 2011, Pediatric blood & cancer.

Curcumin Blocks Kv11.1 (erg) Potassium Current and Slows Proliferation in the Infant Acute Monocytic Leukemia Cell line THP-1

W. Giles, A. Narendran, Anjali Singh, 2011, Cellular Physiology and Biochemistry.

Successful treatment of severe paediatric rheumatic disease-associated macrophage activation syndrome with interleukin-1 inhibition following conventional immunosuppressive therapy: case series with 12 patients.

R. Cron, E. Behrens, A. Narendran, 2011, Rheumatology.

Targeting the Proteasome in Refractory Pediatric Leukemia Cells: Characterization of Effective Cytotoxicity of Carfilzomib

A. Narendran, T. Trippett, Aarthi Jayanthan, 2018, Targeted Oncology.

Ion channels in pediatric CNS Atypical Teratoid/Rhabdoid Tumor (AT/RT) cells: potential targets for novel therapeutic agents

W. Giles, A. Narendran, U. Banderali, 2012, Journal of Neuro-Oncology.

RSK2: a promising therapeutic target for the treatment of triple-negative breast cancer

S. Dunn, G. Los, My-my Huynh, 2019, Expert opinion on therapeutic targets.

Polo‐Like Kinase 1 Inhibition Kills Glioblastoma Multiforme Brain Tumor Cells in Part Through Loss of SOX2 and Delays Tumor Progression in Mice

H. Wakimoto, S. Yip, Chris Jones, 2012, Stem cells.

High-Grade Gliomas

C. Q. Lee, David T. W. Jones, Michael D. Brooks, 2012, Oxford Medicine Online.

Multi-tyrosine kinase inhibitors in preclinical studies for pediatric CNS AT/RT: Evidence for synergy with Topoisomerase-I inhibition

K. Riabowol, P. Bose, A. Narendran, 2011, Cancer Cell International.

Targeted Polo-like Kinase Inhibition Combined With Aurora Kinase Inhibition in Pediatric Acute Leukemia Cells

V. Meier-Stephenson, S. Dunn, A. Narendran, 2019, Journal of pediatric hematology/oncology.

Induction of apoptosis in pediatric acute lymphoblastic leukemia (ALL) cells by the therapeutic opioid methadone and effective synergy with Bcl-2 inhibition.

A. Elwi, A. Narendran, Anjali Singh, 2011, Leukemia research.

Abstract 1038: PMD-026, a first in class oral RSK inhibitor, demonstrates synergy when combined with standard of care in breast cancer tumor models

N. Ueno, S. Dunn, G. Los, 2021, Experimental and Molecular Therapeutics.

Profiling pathway‐specific novel therapeutics in preclinical assessment for central nervous system atypical teratoid rhabdoid tumors (CNS ATRT): Favorable activity of targeting EGFR‐ ErbB2 signaling with lapatinib

Amy A. Smith, P. Forsyth, A. Narendran, 2013, Molecular oncology.

ATYPICAL TERATOID RHABDOID TUMOR (ATRT)

R. Siebert, K. Ligon, C. Roberts, 2012 .

Establishment of atypical-teratoid/rhabdoid tumor (AT/RT) cell cultures from disseminated CSF cells: a model to elucidate biology and potential targeted therapeutics

A. Narendran, D. Strother, D. Bernoux, 2008, Journal of Neuro-Oncology.

The T-type Calcium Channel Cav3.1 in Y79 Retinoblastoma Cells is Regulated by the Epidermal Growth Factor Receptor via the MAPK Signaling Pathway

W. Giles, A. Narendran, M. Jain, 2021, Current eye research.

Inhibition of p90 ribosomal S6 kinases disrupts melanoma cell growth and immune evasion

G. Lenz, S. Dunn, D. Schrama, 2023, Journal of Experimental & Clinical Cancer Research.

First-in-human phase 1/1b expansion of PMD-026, an oral RSK inhibitor, in patients with metastatic triple-negative breast cancer.

M. Beeram, A. Patnaik, S. Dunn, 2021 .

Analysis of Multiple Growth Regulatory Proteins Using Dissociable Staining Antibody Arrays on Solid Tumor Biopsy Specimens

E. Ujack, A. Narendran, Aarthi Jayanthan, 2011, Fetal and pediatric pathology.

Establishment of a t(11;19), KMT2A Rearranged B-ALL Cell Line for Preclinical Evaluation and Novel Therapeutics Development for Refractory Infant Leukemia

A. Narendran, Aarthi Jayanthan, Ravi M. Shah, 2023, Journal of pediatric hematology/oncology.

In Vitro Sensitivity Profiling of Neuroblastoma Cells Against A Comprehensive Small Molecule Kinase Inhibitor Library to Identify Agents for Future Therapeutic Studies.

V. Meier-Stephenson, A. Narendran, Anjali Singh, 2017, Current cancer drug targets.

Druggable targets in pediatric neurocutaneous melanocytosis: Molecular and drug sensitivity studies in xenograft and ex vivo tumor cell culture to identify agents for therapy.

O. Kovalchuk, A. Kirton, Y. Nagashima, 2015, Neuro-oncology.

High grade gliomas

C. Q. Lee, David T. W. Jones, Michael D. Brooks, 2022, Progress in Brain Research.